The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin
Cempra Pharmaceuticals appears to be one of the first companies exploring the newly enacted “limited use” pathway for novel antibiotics. The company cited the approach as an option for fusidic acid for use against MRSA – but it sounds like it may also be on the table for the company’s recently rejected solithromycin.
Register for our free email digests: